France’s Health Minister, Stéphanie Rist, has said that the country is the first in the EU to provide reimbursement coverage for weight-loss therapies, including Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro.
In an interview with French national broadcaster TF1, Rist said limited coverage of the two weekly injectable medicines has been approved, reserving their use only for people with severe obesity, and that the cost of providing them would be around €100 million ($116 million) a year.
They will become an option for severely obese…
